Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observational study for incidence of thromboembolism in lung cancer patients, and the evaluation for efficacy and safety of edoxaban in active cancer patients with venous thromboembolism

Next Previous
Trial Profile

An observational study for incidence of thromboembolism in lung cancer patients, and the evaluation for efficacy and safety of edoxaban in active cancer patients with venous thromboembolism

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edoxaban (Primary)
  • Indications Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms Rising-VTE/NEJ037

Most Recent Events

  • 19 Jun 2022 Status changed from active, no longer recruiting to completed.
  • 08 Jun 2021 Results assessing efficacy and safety of direct oral anticoagulants (DOACs) associated with lung cancer chemotherapy, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
  • 28 Sep 2019 Planned End Date changed from 31 May 2021 to 13 Aug 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top